Tracking doses, timing, subjective effects, and objective measures enables informed protocol adjustment
To understand who is actually a candidate and what monitoring looks like, see our expert review of whether peptides are safe for weight loss, including who is a candidate, what monitoring matters, and the right questions to ask a licensed provider
Further, it is worth noting that oral route of administration is likely to grow at a relatively higher CAGR
Eli Lilly announced the topline results in December 2025: in obese participants with knee osteoarthritis, the 12 mg dose delivered a mean weight loss of 28,7% (32,3 kg / 71,2 lbs) at 68 weeks, and the 9 mg dose delivered a 26,4% reduction
(Switzerland) Altimmune (US) Glenmark Pharmaceuticals Ltd (India) Biocon (India) Teva Pharmaceuticals (Israel) MARKET SCOPE WHAT IS IN IT FOR YOU: GLP-1 Agonists Market REPORT CONTENT GUIDE DELIVERED CUSTOMIZATIONS We have successfully delivered the following deep-dive customizations: RECENT DEVELOPMENTS September 2025 : Novo Nordisk (Denmark) received EU approval for its oral GLP-1 receptor agonist drug, Rybelsus, to reduce cardiovascular death, heart attack, and stroke
This puts Retatrutide among the most effective weight loss drugs currently being researched
